• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors

    6/22/21 8:30:00 AM ET
    $PRAX
    $AGLE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRAX alert in real time by email

    AUSTIN, Texas, June 22, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Marcio Souza to its board of directors. Mr. Souza serves as the president & chief executive officer of Praxis Precision Medicines, Inc. (NASDAQ:PRAX).

    "On behalf of the Aeglea family, I'm pleased to warmly welcome Marcio to our board of directors. We are at a pivotal stage of the company's growth and it is important to have a breadth of experience and diversity of perspectives as we navigate the transition to becoming a commercial-stage company," said Anthony Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. "Marcio brings extensive global operating and commercial experience, with notable expertise in regions outside of the United States and a proven track record in the rare disease space. The insights and perspectives that Marcio brings to the team will be invaluable in shaping the global commercialization strategy for our portfolio of rare metabolic disease treatments."

    "I'm excited to be joining the board of Aeglea, a company committed to having a transformative impact on the lives of patients with rare metabolic diseases," said Mr. Souza. "With Phase 3 data from the Arginase 1 Deficiency program coming in the fourth quarter of 2021 and a second program for Homocystinuria entering the clinic, Aeglea is a company with considerable potential and I look forward to working with the team to bring it to fruition."

    Prior to joining Praxis Precision Medicines, Mr. Souza served as chief operating officer at PTC Therapeutics, Inc. from May 2017 to April 2020 and its senior vice president and head of product strategy from July 2016 to May 2017. Previously, Mr. Souza served in positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc. and Sanofi Genzyme Corporation. He also served on the board of directors of Clearpoint Neuro, Inc. (previously MRI Interventions, Inc.). Mr. Souza received a degree in pharmacy and biochemistry with a specialization in toxicology and clinical analysis from the University of São Paulo and an M.B.A. from Fundação Dom Cabral.

    About Aeglea BioTherapeutics

    Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria in 2020. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.

    Safe Harbor / Forward Looking Statements

    This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our ability to obtain regulatory approval for, and commercialize, pegzilarginase, recognize milestone and royalty payments from our agreement with Immedica, the potential addressable markets of our product candidates, the timing and success of our clinical trials and related data, the timing and expectations for regulatory submissions and approvals, timing and results of meetings with regulators, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, the expected impact of the COVID-19 pandemic on our operations and clinical trials, success in our collaborations, our cash forecasts, and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    (PRNewsfoto/Aeglea BioTherapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-appoints-marcio-souza-to-board-of-directors-301316976.html

    SOURCE Aeglea BioTherapeutics, Inc.

    Get the next $PRAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRAX
    $AGLE

    CompanyDatePrice TargetRatingAnalyst
    Praxis Precision Medicines Inc.
    $PRAX
    5/7/2025$80.00Buy
    Chardan Capital Markets
    Praxis Precision Medicines Inc.
    $PRAX
    3/3/2025$120.00 → $105.00Buy
    H.C. Wainwright
    Praxis Precision Medicines Inc.
    $PRAX
    2/11/2025$111.00Buy
    Deutsche Bank
    Praxis Precision Medicines Inc.
    $PRAX
    8/5/2024$134.00Outperform
    Oppenheimer
    Praxis Precision Medicines Inc.
    $PRAX
    6/24/2024$145.00Buy
    Needham
    Praxis Precision Medicines Inc.
    $PRAX
    6/18/2024$155.00Buy
    Guggenheim
    Praxis Precision Medicines Inc.
    $PRAX
    5/1/2024$117.00Outperform
    Robert W. Baird
    Praxis Precision Medicines Inc.
    $PRAX
    9/19/2023$10.00Buy
    Truist
    More analyst ratings

    $PRAX
    $AGLE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

      BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, hosted a virtual investor event on its clinical programs in developmental and epileptic encephalopathies (DEEs) on Friday, May 2, 2025. "We were excited to highlight the significant opportunity in DEEs and progress Praxis is making in this field," said Marcio Souza, president and chief executive officer of Praxis. "Relutrigine continues to show tremendous promise to broadly address the DEE market

      5/5/25 8:00:00 AM ET
      $IONS
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,688 shares of its common stock to five new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock units were granted as inducements material to the employees' en

      5/2/25 5:00:00 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

      On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen Vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and higher dosing tolerability Praxis to host a virtual investor event on Friday, May 2, 2025 to discuss its DEE portfolio [registration link] Cash and investments of $472 million as of March 31, 2025, maintains runway into 2028 BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc

      5/2/25 8:30:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    $AGLE
    SEC Filings

    See more
    • Praxis Precision Medicines Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)

      5/2/25 5:12:19 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Praxis Precision Medicines Inc.

      10-Q - Praxis Precision Medicines, Inc. (0001689548) (Filer)

      5/2/25 8:38:06 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)

      5/2/25 8:35:39 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    $AGLE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Desimone Jill bought $25,375 worth of shares (14,500 units at $1.75) (SEC Form 4)

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      10/10/23 7:41:39 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    $AGLE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Praxis Precision Medicines with a new price target

      Chardan Capital Markets initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $80.00

      5/7/25 8:38:09 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Praxis Precision Medicines with a new price target

      H.C. Wainwright reiterated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $105.00 from $120.00 previously

      3/3/25 7:53:12 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Praxis Precision Medicines with a new price target

      Deutsche Bank initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $111.00

      2/11/25 7:11:28 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    $AGLE
    Leadership Updates

    Live Leadership Updates

    See more
    • Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD

      Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle, DPhil, appointed as Chief Executive Officer and Member of the Board of Directors alongside industry veterans Jeffrey Albers and Laurie Stelzer Management team with deep IBD experience expanded to advance pipeline of product candidates designed to improve both efficacy and convenience of therapies for IBD patients, including half-life extended antibodies targeting α4β7 (SPY001) and TL1A (SPY002), which are both on track to enter clinical studies in 2024 $205 million of cash, cash equivalents, marketable securities, and restricted cash as of September 30, 2023, with

      11/27/23 8:30:00 AM ET
      $AGLE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

      PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24 BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022

      8/8/22 4:01:00 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

      BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the appointment of Jill DeSimone to its board of directors. "We are very excited to have Jill join the Praxis board of directors. She is an ideal fit for the Praxis board with her impressive background as a global business leader for multi-billion-dollar products, unique insights into product strategy and portfolio prioritization, and breadth of experience advocating for excellence

      5/23/22 9:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    $AGLE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel and Secretary Nemiroff Alex covered exercise/tax liability with 51 shares, decreasing direct ownership by 0.24% to 20,832 units (SEC Form 4)

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      2/14/25 4:29:47 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Principal Accounting Officer Mastrocola Lauren covered exercise/tax liability with 40 shares, decreasing direct ownership by 0.38% to 10,442 units (SEC Form 4)

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      2/14/25 4:29:37 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Souza Marcio covered exercise/tax liability with 401 shares, decreasing direct ownership by 0.74% to 53,559 units (SEC Form 4)

      4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

      2/14/25 4:29:25 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    $AGLE
    Financials

    Live finance-specific insights

    See more
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment
    • Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

      Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study recruiting following unprecedented seizure freedom seen in positive topline EMBOLD results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) Vormatrigine (PRAX-628) on track for topline from POWER1 study in focal epilepsy and RADIANT study in focal and generalized epilepsy in 2025 Maintains runway into 2027 BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic i

      11/6/24 7:30:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

      BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024. The Company will host a live webcast the same morning at 8am ET, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media se

      11/1/24 8:00:00 AM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRAX
    $AGLE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

      SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      11/14/24 7:53:30 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

      SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      11/14/24 5:50:15 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

      SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

      11/14/24 5:46:12 PM ET
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care